NewAmsterdam Pharma N.V. Financial Ratios
NASDAQ: NAMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
21.58+0.315 (+1.48%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NewAmsterdam Pharma N.V. ratio analysis
NewAmsterdam Pharma N.V. earned a net margin of -905.7% in FY 2025, down from -530.3% a year earlier. Return on equity reached -29.8%, meaning NewAmsterdam Pharma N.V. generated -0.30 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
NewAmsterdam Pharma N.V. financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Price / sales | 185.24 | 53.72 | 65.13 | 2.01 | — |
| Price / book | 6.10 | 3.23 | 3.18 | 0.48 | — |
| Operating margin | -1,002.9% | -386.9% | -1,298.6% | -3.5% | — |
| Net margin | -905.7% | -530.3% | -1,255.8% | -22.0% | — |
| Free cash flow margin | -657.8% | -349.5% | -1,002.4% | 10.2% | — |
| Return on equity (ROE) | -29.8% | -31.9% | -61.4% | -5.3% | — |
| Return on assets (ROA) | -26.5% | -27.9% | -51.0% | -4.7% | — |
| Current ratio | 7.88 | 8.08 | 6.95 | 13.26 | — |
| Revenue growth | -50.6% | 223.4% | -86.3% | — | — |